Teva Reports Positive Phase 2a Trial Results for Celiac Disease Drug Candidate
Translated & summarized from Bizportal by baba
Teva Pharmaceuticals has reported positive Phase 2a trial results for its celiac disease drug candidate, TEV-'408, which significantly reduced gluten-induced intestinal damage. The company is also developing the drug for vitiligo and has secured significant funding for its advancement.
The story in 5 lines · by baba
- Teva's TEV-'408 antibody showed positive results in a Phase 2a celiac disease trial.
- The drug significantly reduced gluten-induced intestinal damage compared to placebo.
- TEV-'408 targets the IL-15 pathway and is also being tested for vitiligo.
- The FDA granted Fast Track designation for TEV-'408 in celiac disease.
- Teva secured up to $500 million in funding for the drug's development.
Teva Pharmaceuticals announced positive results from a Phase 2a clinical trial for TEV-'408, an investigational antibody designed to treat conditions including celiac disease. The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in gluten-induced intestinal damage compared to a placebo.
The study involved 50 adult celiac patients adhering to a gluten-free diet who experienced minimal intestinal damage at the trial's outset. After receiving a single subcutaneous dose of TEV-'408, participants underwent controlled daily gluten exposure for six weeks. Eight weeks later, the treatment group showed less damage to the intestinal lining than the placebo group, indicating a protective effect against gluten-induced harm.
Beyond the primary goal, Teva reported positive impacts on intestinal inflammation markers and lower gastrointestinal symptom scores in the treatment group. The company stated the drug was well-tolerated with no new safety concerns identified. TEV-'408 targets IL-15, a protein involved in inflammatory and immune pathways, aiming to reduce the immune response that damages the intestine after gluten exposure.
In May 2025, TEV-'408 received Fast Track designation from the FDA for celiac disease. Teva is also exploring TEV-'408 for vitiligo, with positive Phase 1b results leading to a Phase 2b trial. This multi-indication potential leads Teva to describe the molecule as a "pipeline-in-a-product."
Financially, Teva partnered with Royalty Pharma in January, potentially receiving up to $500 million to accelerate TEV-'408's clinical development. Celiac disease, an autoimmune disorder affecting about 1% of the global population, currently lacks an approved drug treatment beyond gluten avoidance. Teva plans to present further data at a scientific conference and will hold an investor call to discuss development plans, including future trial sizes and the asset's potential within its innovative drug pipeline.
The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.
Left 1Centre 5Right 2Other 7
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.